Hybrid Imaging Modalities for the Evaluation of Infection - Full Text View

Sponsored by:	Rambam Health Care Campus
Information provided by:	Rambam Health Care Campus
ClinicalTrials.gov Identifier:	NCT00230152

Purpose

The synergistic value of the fusion of physiologic and anatomical data has been described using several co-registration techniques for various nuclear medicine procedures and morphologic imaging modalities (single photon emission computed tomography-computed tomography [SPECT-CT], SPECT-magnetic resonance imaging [MRI], camera-based positron emission tomography [PET]-CT and PET-CT). The researchers hypothesize that fusion of nuclear medicine (NM) and CT data acquired sequentially in a single imaging session on one device is clinically superior to side-by-side evaluation of separately performed imaging tests. They hypothesize that more accurate localization of increased radiotracer activity on NM procedures will improve the diagnostic accuracy for detection of infection and will subsequently have a significant impact on patient management.

The purpose of the present study is to assess the clinical value of this new technology of fused imaging in patients undergoing diagnostic nuclear medicine evaluation for suspicion of an infection process.

Condition	Intervention
Infectious Diseases	Device: PET-CT imaging Device: SPECT-CT imaging

MedlinePlus related topics: Nuclear Scans

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment
Official Title:	Nuclear Medicine for the Evaluation of Infection-the Added Value of Hybrid Imaging Modalities

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:

The impact of the imaging modality on patient management

Estimated Enrollment:	150
Study Start Date:	February 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients referred for NM imaging procedures to assess the presence of infectious processes.
Patients signed informed consent

Exclusion Criteria:

The study will not be performed in pregnant or lactating women.
Patients unable or unwilling to tolerate the scan until its completion

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230152

Contacts

Contact: Zohar Kiedar, MD, PhD	972-4-8543009	zohar@keidar.net
Contact: Rachel Bar-Shalom, MD	972-4-8543009	r_bar_shalom@rambam.health.gov.il

Locations

Israel
Rambam Medical Center	Recruiting
Haifa, Israel
Contact: Zohar Kiedar, MD, PhD 972-4-8543009 zohar@kiedar.net
Principal Investigator: Zohar Kiedar, MD, PhD
Sub-Investigator: Rachel Bar-Shalom, MD

Sponsors and Collaborators

Rambam Health Care Campus

Investigators

Principal Investigator:

Zohar Keidar, MD, PhD

Rambam Health Care Campus

More Information

Study ID Numbers:	infectionCTIL
Study First Received:	September 29, 2005
Last Updated:	February 13, 2006
ClinicalTrials.gov Identifier:	NCT00230152
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:

Communicable Diseases
Infection

ClinicalTrials.gov processed this record on January 14, 2009